[New therapeutic strategies in non-Hodgkin lymphomas and Hodgkin lymphoma]. / Actualités thérapeutiques dans les lymphomes non hodgkiniens et le lymphome de Hodgkin.
Rev Med Interne
; 40(4): 246-254, 2019 Apr.
Article
in Fr
| MEDLINE
| ID: mdl-29801709
ABSTRACT
In this review, we report the main advances of the last years in the four most common lymphomas in France, namely Hodgkin lymphoma, large cell diffuse B lymphoma, follicular lymphoma and mantle cell lymphoma. We have identified consensual practices in first line in France and then distinguished the targeting by new molecules. Thus, we wanted to highlight the problems for each of these four lymphomas and understand the tools used to find solutions. Finally, this review makes it possible to understand to what extent the new molecules (targeted therapies, immunotherapy) make it possible to continuously improve the management of patients with lymphomas. The global dynamics seems to reduce the place of conventional chemotherapies in favor of these new molecules. However, because of the increase in therapeutic possibilities, the challenge remains to find the combination associated with the best risk-benefit ratio.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Lymphoma, Non-Hodgkin
/
Hodgkin Disease
/
Therapies, Investigational
Limits:
Humans
Language:
Fr
Journal:
Rev Med Interne
Year:
2019
Document type:
Article